MedTrace Logo

Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

NCT00008749 · Status: UNKNOWN · Type: OBSERVATIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.

Conditions

  • Lupus Erythematosus, Systemic

Sponsors & Collaborators

  • Arthritis Foundation

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    lead NIH

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00008749 on ClinicalTrials.gov